Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

• Status: Completed
• Trial end date: 2016-06-29
• Target enrollment: 0
• Participant gender: All

Summary

This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Antibodies, Monoclonal; Ustekinumab

Criteria

Inclusion Criteria:

• patients with moderate to severe plaque type psoriasis for at least 6 months before randomization

• patients eligible for systemic therapy with inadequately controlled psoriasis

Exclusion Criteria:

• forms of sporiasis other than plaque type psoriasis

• previous exposure to secukinumab, ustekinumab, or other biologic drugs targeting (IL)-17A or IL-17RA

Other protocol-defined inclusion/exclusion criteria may apply